Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts.

ABSTRACT: Acquired drug resistance represents a major obstacle to using sunitinib for the treatment of solid tumors. Here, we examined the cellular and molecular alterations in tumors that are associated with acquired brain tumor resistance to sunitinib by using an in vivo model. U87MG tumors obtained from nude mice that received sunitinib (40 mg/kg/day) for 30 days were classified into sunitinib-sensitive and -resistant groups based on tumor volume and underwent targeted gene microarray and protein array analyses. The expression of several angiogenesis-associated genes was significantly modulated in sunitinib-treated tumors compared with those in control tumors (p<0.05), whereas no significant differences were observed between sunitinib-sensitive and -resistant tumors (p>0.05). Tumor vasculature ba

SUBMITTER: Zhou Q 

PROVIDER: S-EPMC3477209 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature